Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

Ricardo D. Parrondo; Aneel Paulus; Victoria Alegria; David Liebowitz; Chelsea Johnson; Raphael Clynes; Vivek Roy; David M. Menke; Liuyan Jiang; Asher A. Chanan-Khan; Sikander Ailawadhi

doi:10.1080/10428194.2021.2005045

Plamotamab (XmAb^®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

Ricardo D. Parrondo, Aneel Paulus, Victoria Alegria, David Liebowitz, Chelsea Johnson, Raphael Clynes, Vivek Roy, David M. Menke, Liuyan Jiang, Asher A. Chanan-Khan, Sikander Ailawadhi

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	738-742
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	63
Issue number	3
DOIs	https://doi.org/10.1080/10428194.2021.2005045
State	Published - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2021.2005045

Cite this

@article{78fc0b0db7fb412eb1da2a2d1fc56453,

title = "Plamotamab (XmAb{\textregistered}13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr{\"o}m macroglobulinemia",

author = "Parrondo, {Ricardo D.} and Aneel Paulus and Victoria Alegria and David Liebowitz and Chelsea Johnson and Raphael Clynes and Vivek Roy and Menke, {David M.} and Liuyan Jiang and Chanan-Khan, {Asher A.} and Sikander Ailawadhi",

note = "Funding Information: S.A receives honoraria from Celgene and Takeda as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune and Phosplatin. ",

year = "2022",

doi = "10.1080/10428194.2021.2005045",

language = "English (US)",

volume = "63",

pages = "738--742",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

AU - Parrondo, Ricardo D.

AU - Paulus, Aneel

AU - Alegria, Victoria

AU - Liebowitz, David

AU - Johnson, Chelsea

AU - Clynes, Raphael

AU - Roy, Vivek

AU - Menke, David M.

AU - Jiang, Liuyan

AU - Chanan-Khan, Asher A.

AU - Ailawadhi, Sikander

N1 - Funding Information: S.A receives honoraria from Celgene and Takeda as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune and Phosplatin.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85119320006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119320006&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.2005045

DO - 10.1080/10428194.2021.2005045

M3 - Letter

C2 - 34781809

AN - SCOPUS:85119320006

SN - 1042-8194

VL - 63

SP - 738

EP - 742

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Plamotamab (XmAb^®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia